Track record and alliances
Both technologies are used in collaborative drug discovery projects with Pharma companies. In addition, Polyphor is developing advanced research programs and a pre-clinical and clinical portfolio of own drug candidates (PEMdrugs) in important disease areas which are offered for partnering/out-licensing in various stages of development.
Polyphor has an excellent reputation as a generator of innovation in drug discovery. We are proud of our strong track record and long-lasting business relations that we have been able to establish over more than ten years during which we have supported our Pharma partners in their small molecule drug discovery efforts.
Since 1996, Polyphor collaborated with many pharma partners in Europe, Japan and the US by providing support in hit identification, hit to lead or lead optimization projects. Several of these business relations are uninterrupted after more than 10 years. More and more, such collaborations develop into comprehensive medicinal chemistry collaborations in which Polyphor applies all its capabilities of drug discovery including design, synthesis development, protein expression, assay development, ADMET screening and structural biology.